Live News Categoriesequity

Orum Therapeutics, Inc. (475830.KQ) News

Follow Orum Therapeutics, Inc. (475830.KQ) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol 475830.KQ Asset equity Sector Markets 90 days 1 Last 17,600 Updated Oct 13, 2026, 11:01 PM UTC Open live news feed

L Orum Therapeutics doses first patient in Phase 1 trial of AML drug candidate ORM — 1153 Orum Therapeutics dosed the first patient in a Phase 1 trial of ORM-1153 for relapsed or refractory AML. No clinical results have been presented; the study is designed to generate initial safety, pharmacology, and early NEWS | Oct 13, 2026, 11:01 PM UTC